{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '9.6.', 'Safety Monitoring', '93', '9.7.', 'Investigator Alert Notification', '93', '10.', 'STATISTICAL PLAN', '93', '10.1.', 'Statistical Hypothesis', '93', '10.2.', 'Justification of Sample Size', '94', '10.3.', 'Analysis Sets', '94', '10.3.1.', 'Efficacy Analysis Sets', '94', '10.3.2.', 'Safety Analysis Set', '94', '10.3.3.', 'Other Analysis Sets', '95', '10.4.', 'Statistical Methods', '95', '10.4.1.', 'Patient Disposition', '95', '10.4.2.', 'Demography and Baseline Characteristics', '95', '10.4.3.', 'Medical History', '96', '10.4.4.', 'Prior Medications/Concomitant Medications', '96', '10.4.5.', 'Efficacy Analyses', '96', '10.4.5.1.', 'Primary Efficacy Analysis', '96', '10.4.5.2.', 'Secondary Efficacy Analysis', '96', '10.4.5.3.', 'Quality of Life Analysis', '97', '10.4.5.4.', 'Exploratory Efficacy Endpoint Analysis', '97', '10.4.5.5.', 'Subgroup Analyses', '97', '10.4.6.', 'Safety Analysis', '97', '10.4.6.1.', 'Adverse Events', '98', '10.4.6.2.', 'Other Safety', '98', '10.4.6.3.', 'Treatment Exposure', '99', '10.4.6.4.', 'Treatment Compliance', '99', '10.4.7.', 'Analysis of Drug Concentration Data', '99', '10.4.8.', 'Analysis of Anti-Drug Antibody Data', '99', '10.4.9.', 'Analysis of Biomarker Data', '99', '10.5.', 'Interim Analysis', '99', '10.6.', 'Additional Statistical Data Handling Conventions', '100', '10.7.', 'Statistical Considerations Surrounding the Premature Termination of a Study', '101', '11.', 'DATA MANAGEMENT AND ELECTRONIC SYSTEMS', '101', '11.1.', 'Data Management', '101', 'Regeneron Pharmaceuticals, Inc.', 'Page 24 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '11.2.', 'Electronic Systems', '101', '12.', 'STUDY MONITORING', '102', '12.1.', 'Monitoring of Study Sites', '102', '12.2.', 'Source Document Requirements', '102', '12.3.', 'Case Report Form Requirements', '102', '13.', 'AUDITS AND INSPECTIONS', '102', '14.', 'ETHICAL AND REGULATORY CONSIDERATIONS', '103', '14.1.', 'Good Clinical Practice Statement', '103', '14.2.', 'Informed Consent', '103', '14.3.', 'Patient Confidentiality and Data Protection', '103', '14.4.', 'Institutional Review Board/Ethics Committee', '104', '15.', 'PROTOCOL AMENDMENTS', '104', '16.', 'PREMATURE TERMINATION OF THE STUDY OR CLOSE-OUT OF', 'A', 'SITE', '104', '16.1.', 'Premature Termination of the Study', '104', '16.2.', 'Close-out of a Site', '104', '17.', 'STUDY DOCUMENTATION', '105', '17.1.', 'Certification of Accuracy of Data', '105', '17.2.', 'Retention of Records', '105', '18.', 'CONFIDENTIALITY', '105', '19.', 'FINANCING AND INSURANCE', '106', '20.', 'PUBLICATION POLICY', '106', '21.', 'REFERENCES', '107', '22.', \"INVESTIGATOR'S AGREEMENT\", '111', \"SIGNATURE OF SPONSOR'S RESPONSIBLE OFFICERS\", '145', 'Regeneron Pharmaceuticals, Inc.', 'Page 25 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}